On Wednesday, in the course of current trade, Shares of Burlington Stores, Inc. (NYSE:BURL), dropped -0.79%, and is now trading at $48.96.
Burlington Stores, declared its results for the first quarter ended May 2, 2015.
Tom Kingsbury, Chairman and Chief Executive Officer stated, “We are happy with our 64% enhance in adjusted EPS which was driven by a robust gross margin expansion. While our comp sales were positive for the ninth successive quarter, we were negatively influenced by the timing of IRS tax refunds, lower markdown sales due to significantly less markdown inventory, raised store closures due to weather, and receipt flow issues in three key Easter businesses. With that said, I am optimistic about our business as comparable store sales have accelerated and we are in a great inventory position to take advantage of the many opportunities we see in the market place.”
Burlington Stores, Inc. operates as a retailer of branded apparel products in the United States. The company offers fashion-focused merchandise, counting women’s ready-to-wear apparel, menswear, youth apparel, baby products, footwear, accessories, home décor and gifts, and coats.
During an Afternoon trade, Shares of Medtronic plc (NYSE:MDT), gained 1.63%, and is now trading at $76.14.
Furthering its commitment to fight obesity with innovative bariatric surgical solutions, Medtronic, now offers the GastriSail(TM) gastric positioning system to assist promote more consistent sleeve creation and greater procedural efficiency within the sleeve gastrectomy procedure, the most commonly performed weight loss procedure in the U.S.
Developed by Medtronic`s Minimally Invasive Therapies Group, the GastriSail system combines the benefits of three devices into one, allowing surgeons to consistently size and decompress the stomach pouch and test for leaks without removing and reinserting another device. With fewer device insertions, there is potentially less risk of irritating or injuring the esophagus during the procedure1. The GastriSail system received U.S. Food and Drug Administration 510(k) clearance in February 2015.
“The GastriSail system provides improved visualization and improved consistency allowing for streamlined, auto-placement in the stomach,” said Amit Trivedi, MD, bariatric surgeon at Hackensack University Medical Center in Hackensack, NJ, and co-developer of the GastriSail system. “Using the GastriSail system enables a more consistent procedure and greater efficiency, which can potentially change the patient experience.”
During a sleeve gastrectomy procedure, surgeons use minimally invasive approaches to remove about two-thirds of the stomach to create a small sleeve-shaped pouch. With the new smaller stomach, the patient will feel full faster after eating a small amount of food in a single sitting.
Medtronic plc, a healthcare solutions company, provides medical technologies, services, and solutions worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group.
Finally, Orexigen Therapeutics, Inc. (NASDAQ:OREX), lost -1.47% Wednesday.
Orexigen Therapeutics, declared that two Contrave® (naltrexone HCI and bupropion HCI) abstracts will be presented at the forthcoming annual meeting of the American Diabetes Association being held in Boston June 5 – 9, 2015 at the Boston Convention and Exposition Center.
The abstracts are the first presentations of data from the randomized, open-label Ignite Study, which was designed to provide additional information regarding Contrave in combination with a behavioral modification program, contrast to patients who received diet and exercise advice but who did not receive Contrave. Consistent with current labeling for recently approved anti-obesity medications, the 242 patients randomized into the study were required to achieve a certain amount of weight loss (at least 5% at week 16) and to not have a meaningful enhance in blood pressure to remain on medication. The primary endpoint for this trial was change in body weight after 26 weeks in the per-protocol population. Secondary endpoints comprised of the percentage of patients achieving at least 5% and 10% weight loss, waist circumference, lipids, and measures of glucose homeostasis, in addition to a number of other key measures.
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
